A quarter in change
AddLife´s interim report for Q2 2022 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q2-2022
1 APRIL -
- Net sales decreased by 9 percent to
SEK 2,079m (2,276), of which acquired growth amounted to 13 percent. The COVID-19 related net sales decreased by 88 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent. -
EBITA decreased by 28 percent to
SEK 240m (332), corresponding to an EBITA-margin of 11.6 percent (14.6). -
Profit after tax decreased by 57 percent to
SEK 76m (178). -
Earnings per share amounted to
SEK 0.63 (1.47). -
Cash flow from operating activities amounted to
SEK 206m (200). -
During the quarter, two acquisitions, BioCat GmBh and O'
Flynn Medical Ltd , were completed and after the end of the quarter, one more acquisition,JK Lab Nordic AB , were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximatelySEK 180m and approximately 60 employees.
1 JANUARY -
- Net sales increased by 16 percent to
SEK 4,658m (4,012), of which acquired growth amounted to 30 percent. The COVID-19 related net sales decreased by 59 percent. The organic growth, excluding net sales related to COVID-19, was 3 percent. -
EBITA increased by 3 percent to
SEK 675m (658), corresponding to an EBITA-margin of 14.5 percent (16.4). -
Profit after tax decreased by 26 percent to
SEK 301m (404). -
Earnings per share amounted to
SEK 2.47 (3.46). Earnings per share for the last 12 months amounted toSEK 5.07 (6.03). -
Cash flow from operating activities amounted to
SEK 538m (384). - The equity ratio was 36 percent (40).
- Return on working capital (P/WC) amounted to 74 percent (95).
-
During the interim period, four acquisitions were made and another after the end of the interim period. The acquisitions are expected to contribute with annual net sales of approximately
SEK 855m . AddLife 's new President and CEOFredrik Dalborg will start onSeptember 1st .
For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life, +46 70 510 12 23
Christina Rubenhag, CFO, christina.rubenhag@add.life, ++46 70 546 72 22
www.add.life
Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO
The teleconference will be at
If you wish to participate via teleconference, please follow this link>>
Or call in (only sound) +46 8 505 376 58 Conference-ID: 915 124 356#
The presentation is also available on AddLife YouTube >>
This information is information that
https://news.cision.com/addlife/r/interim-report-1-january---30-june-2022,c3601603
https://mb.cision.com/Main/13919/3601603/1604616.pdf
(c) 2022 Cision. All rights reserved., source